1.45
-0.02
(-1.69%)
May 21 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | - |
| 52 week | 0.50 - 1.85 |
| Open | 1.48 |
| Vol. | 0.00 |
| Mkt cap | 2.88M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.01* |
| Shares | 198.82M |
| Beta | - |
| Inst. own | - |
| *GBP |
Key stats and ratios
| Q2 (Jun '12) | 2011 | |
| Net profit margin | -130.50% | -200.79% |
| Operating margin | -130.74% | -215.84% |
| EBITD margin | - | -186.41% |
| Return on average assets | -32.47% | -49.10% |
| Return on average equity | -36.24% | -56.83% |
| Employees | 4,000 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Akers Biosciences, Inc. (ABI) is focused on the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company�s main product is a disposable breathalyzer test that measures the blood alcohol content of the user. ABI�s portfolio is derived from four of the Company�s six platform technologies: Particle ImmunoFiltration Assay (PIFA), Micro Particle Catalyzed (MPC) Biosensor, Rapid Enzymatic Assay (REA) and Synthetic Macrocycle Complex (SMC). The core products marketed under the PIFA platform are the PIFA Heparin/PF4 Rapid Assay, a variety of rapid infectious disease screening tests, and the Battlefield Blood Transfusion Card.
Officers and directors
| Raymond F. Akers Jr., Ph.D. | Executive Chairman of the Board | |
| Thomas A. Nicolette | President, Chief Executive Officer, Executive Director | |
| Patrice Laterra McMorrow | Vice President - Marketing | |
| Gary M. Rauch | Financial Controller |